BlossomHill Therapeutics, Inc. Common Stock (BLSM)

BlossomHill Therapeutics, Inc. Common Stock (BLSM) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $458M; returns 1 day -7.5%, 1 week +4.9%.

BlossomHill Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for oncology and autoimmune diseases. As of August 2026, the company is pre-revenue, having recently completed an upsized $150 million IPO on the Nasdaq.

Groups BLSM belongs to

• Clinical Stage Biotech
• Recent IPOs
• Biotechnology
• Biopharmaceutical
• Oncology
• Clinical Stage
• Healthcare
• Cancer Therapeutics
• Life Sciences
• Autoimmune Diseases
• Drug Discovery

BLSM financial model: income statement, cash flow and balance sheet